On October 2, WUXI APPTEC fell 3.07% in regular trading, trading at 208.2 HKD/share, with turnover of HKD 177 million.
Within the Life Sciences Tools & Services sector where WUXI APPTEC belongs, the sector saw broad-based weakness. Among individual stocks, WUXI BIO down 3.3%, GENSCRIPT BIO down 3.52%, INSILICO down 5.82%, WUXI XDC down 4.45%, XTALPI down 5.5%.
WUXI APPTEC is a leading global pharmaceutical and life sciences integrated service provider. The company operates through a CRDMO business model, offering end-to-end drug R&D and manufacturing services spanning small molecule chemistry, biologics research, preclinical testing, and clinical development across operations in Asia, Europe, and North America. As of mid-year, the company carried backlog orders of RMB 66.43 billion, up 25.2% year-over-year.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)